

**Preliminary Scientific Program  
As of October 25, 2018**

<b>Plenary Session</b>	<b>Parallel Session</b>	<b>Oral Presentation Session</b>	<b>Industry Session</b>	<b>Break</b>
------------------------	-------------------------	----------------------------------	-------------------------	--------------

**Wednesday, 20 February 2019**

<b>14:30-16:00</b>	<b>PARALLEL INDUSTRY SYMPOSIUM</b>	<b>PARALLEL INDUSTRY WORKSHOP</b>		<b>PARALLEL INDUSTRY SYMPOSIUM</b>
<b>16:15-17:45</b>	<b>PARALLEL INDUSTRY WORKSHOP</b>	<b>PARALLEL INDUSTRY WORKSHOP</b>	<b>PARALLEL INDUSTRY WORKSHOP</b>	<b>PARALLEL INDUSTRY WORKSHOP</b>
<b>18:00-19:00</b>	<b>OPENING CEREMONY</b>			
	Tadej Battelino - Opening Remarks			
	Lutz Heinemann – Future of Diabetes Technology – where are we going from here?			
<b>19:00-20:00</b>	<b>NETWORKING RECEPTION (In the Exhibition Area)</b>			

## Thursday, 21 February 2019

08:30-10:00	<b>PLENARY SESSION DECISION SUPPORT SYSTEMS (DSS)</b>					
	<p><b>Rich Bergenstal</b>- Do we need diabetes decision support systems?</p> <p><b>Bruce Bode</b> - Use of Decision Support System in the Hospital</p> <p><b>Moshe Phillip</b> - Advice4U – Decision Support Systems for healthcare professionals</p> <p><b>Courtney Lias</b> – Regulatory aspects of the use of Decision Support Systems</p>					
10:00-10:30	<b>COFFEE BREAK</b>					
10:30-12:00	<b>PLENARY INDUSTRY SYMPOSIUM</b>					
12:00-13:00	<b>LUNCH BREAK</b>					
13:00-14:30	<b>PARALLEL SESSION NEW AVENUES IN PROTEIN DRUGS FOR DIABETES</b>	<b>PARALLEL SESSION TIME IN RANGES (TIRs)</b>	<b>PARALLEL SESSION NUTRITION AND FOOD TECHNOLOGY</b>	<b>JDRF PARALLEL SESSION TOWARD NEXT- GENERATION PHYSIOLOGIC AUTOMATED INSULIN DELIVERY (AID) SYSTEMS: A PROMISING FRONTIER</b>	<b>PARALLEL INDUSTRY</b>	<b>PARALLEL INDUSRY</b>

	<p><b>Cliff Bailey</b> - Targeting more than one receptor</p> <p><b>Melanie Davies</b> - Oral absorption of protein drugs</p> <p><b>Tim Heise</b> - Smart insulins</p> <p><b>Jessica Castle</b> - Stable Glucagon</p>	<p><b>Simon Heller</b> - Exploring and explaining the rationale for a new and extending classification of hypoglycemia in an era of CGM</p> <p><b>Roy Beck</b> - Time in Range as an outcome in clinical trials</p> <p><b>Irl Hirsch</b> – Time in Range(s) vs. HbA1c: Are Our Patients Ready to Change?</p> <p><b>Tadej Battelino</b> – Time in Range – towards a consensus</p>	<p><b>Ram Weiss</b> - personalized nutrition: the time has come?</p> <p><b>Michal Gillon</b> - Complementary sensors technologies for food consumption monitoring</p> <p><b>Andrea Scaramuzza</b> - Efficacy of an app to count carbs to limit the post-meal glucose rise in children with type 1 diabetes</p>	<p><b>Jaime Giraldo</b> - JDRF Strategy and Perspective</p> <p><b>Eric Renard</b> - Current Status of Physiologic Insulin Delivery: Clinical Benefits and Challenges</p> <p><b>Eyal Dassau</b> - Algorithms for Automated Delivery of Insulin in the Intraperitoneal (IP) Space</p> <p><b>Guillermo Arreaza-Rubin</b> - Implantable IP AID Systems: Assessment of Needs</p> <p><b>Jackie Le Grand</b> - Opportunities and Challenges in Adoption of and Access to Implantable IP AID Systems</p> <p><b>Moderated Panel Q&amp;A</b>  Moderator - <b>Daniel Finan</b>  Panel - <b>Eric Renard, Eyal Dassau, Guillermo Arreaza-Rubin, Katharine Barnard, Anne Nordyke, Greg Peterson</b></p>		
--	---	--	--	---	--	--

14:30-15:00	COFFEE BREAK
-------------	--------------

15:00-16:30	PLENARY INDUSTRY SYMPOSIUM
-------------	----------------------------

16:40- 18:00	PARALLEL SESSION COGNITION IN DIABETES	PARALLEL SESSION NOVEL BIOMARKERS FOR DIABETES	PARALLEL SESSION CLOSED-LOOP SYSTEMS – WHERE ARE WE NOW?	PARALLEL INDUSTRY	ORAL 1	ORAL 2
	<p><b>Pratik Choudhary</b> – Impact of hypoglycemia on cognitive function</p> <p><b>Jasna Šuput Omladič</b> – Impact of Hyperglycemia on cognitive function</p> <p><b>Stuart Weinzimer</b> - Brain and cognitive consequences of type 1 diabetes (T1D) – the DirecNet Project</p> <p><b>Stephanie Amiel</b> - Hypo in clinical trials and vice-versa</p>	<p><b>Lorena Wright</b> - Novel Diabetes Biomarkers: An Update of 1,5 AG for the Clinician</p> <p><b>Marcello Ciaccio</b> - Glycated Albumin: from biochemistry to clinical applications</p> <p><b>Markus Stoffel</b>- non-codingRNA in Diabetes</p> <p><b>Desmond Schatz</b> – Novel Biomarkers identified by international prevention-studies</p>	<p><b>Bruce Bode</b> - Outcomes of the Medtronic 670G in diabetes clinics in the USA</p> <p><b>Roman Hovorka</b> – Progress on using Cambridge Closed-Loop algorithm</p> <p><b>Eyal Dassau</b> – Harvard's experience with closed-loop</p> <p><b>Sue Brown</b> – Virginia's experience with closed-loop</p> <p><b>Tadej Battelino</b> – update from the FLAIR study</p> <p><b>Ahmad Haidar</b> – Pramlintide in the artificial pancreas</p> <p><b>John Pickup</b> - values vs. affordability of diabetes technology</p>			

## Friday, 22 February 2019

08:00-08:50	<b>PLENARY INDUSTRY MORNING SYMPOSIUM</b>					
09:00- 10:00	<b>PARALLEL SESSION NEW MODELS OF IMPLEMENTING CGM</b>	<b>PARALLEL SESSION ADJUNCTIVE THERAPIES FOR T1D</b>	<b>PARALLEL SESSION PSYCHOLOGICAL INTERVENTION TO INCREASE THE USE OF TECHNOLOGY BY T1D PATIENTS</b>	<b>Oral 3</b>	<b>PARALLEL INDUSTRY</b>	<b>PARALLEL INDUSTRY</b>
	<p><b>Tom Martens</b> – CGM use in a primary care network</p> <p><b>Amit Majithia</b> - CGM for type 2 diabetes – direct to consumer</p> <p><b>Roy Beck</b> – CGM use for type 1 diabetes – direct to consumer</p>	<p><b>Satish Garg</b> – Emerging role of Adjunctive Therapies for T1D</p> <p><b>Chantal Mathieu</b> - The concept of SGLT in diabetes</p> <p><b>Thomas Danne</b> - Report on the consensus on SGLT in T1D</p>	<p><b>Alon Liberman</b> - Introduction</p> <p><b>Susana R. Patton</b> - Adherence to Insulin Pump Behaviors in Young Children with Type 1 Diabetes Mellitus: Opportunities for Intervention</p> <p><b>Katharine Barnard</b> - Psychosocial Aspects &amp; Diabetes Technology- Head to Head or Hand in Hand?</p> <p><b>Korey Hood</b> - Preventing poor psychosocial and glycemic outcomes in teens with type 1 diabetes</p>			
10:00-10:30	<b>COFFEE BREAK</b>					
10:30-12:00	<b>PLENARY INDUSTRY SYMPOSIUM</b>					
12:00-13:00	<b>LUNCH BREAK</b>					
13:00-14:30	<b>PLENARY SESSION - ATTD YEARBOOK</b>					

14:30-15:00	COFFEE BREAK					
15:00-16:30	PLENARY INDUSTRY SYMPOSIUM					
16:40- 18:10	<b>PARALLEL SESSION PATIENT DECISION SUPPORT: CONCEPT AND TOOLS</b>	<b>PARALLEL SESSION PATIENT-REPORTED OUTCOME MEASURES (PROMS) AND OUTCOME DRIVEN MEDICINE</b>	<b>PARALLEL SESSION DIABETES EDUCATION</b>	<b>Parallel industry</b>	<b>Parallel Industry</b>	<b>Parallel Industry</b>
	<p><b>Boris Kovatchev</b> - Decision support system for patients with diabetes: concept, goals and feasibility</p> <p><b>Pau Herrero</b> - A better care for diabetes</p> <p><b>Lutz Heinemann</b> - Integrated Personalized Diabetes Management: Results of the Pro Value Studies</p> <p><b>Revital Nimri</b> - Decision Support Systems directly to the patients</p>	<p><b>Katharine Barnard</b> - Evaluation of Patient-Reported Outcome Measures (PROMs).</p> <p><b>Neal Kaufman</b> – Evidence-based behavior change intervention</p> <p><b>Michael Riddell</b> – PROMs, Apps and Exercise in Diabetes</p> <p><b>Mark Palmert</b> - A Mobile App for the Self-Management of Type 1 Diabetes Among Adolescents: A Randomized Controlled Trial</p>	<p><b>Andrea Scaramuzza</b> - Education in Predictive Low Glucose Management (<i>PLGM</i>)</p> <p><b>Debate:</b> What is more important:</p> <p><b>Lori Laffel</b> - Structured education</p> <p><b>Hood Thabit:</b> Diabetes Technology (closed-loop)</p> <p><b>Laurel Messer</b> - The importance of education in Closed-loop</p> <p><b>Goran Petrovski</b> - Education through Facebook and other social media</p>			

**Saturday, 23 February 2019**

<p><b>08:30-10:00</b></p>	<p><b>PARALLEL SESSION THERAPIES IN TYPE 2 DIABETES</b></p>	<p><b>PARALLEL SESSION WHAT PATIENTS DO WITH CGM DATA AND WHAT THEY SHOULD DO</b></p>	<p><b>PARALLEL SESSION DATA DIABETES SCIENCE</b></p>	<p><b>ORAL 4</b></p>	<p><b>ORAL 5</b></p>
	<p><b>Richard Bergenstal</b> – Does MDI therapy really work in T2D</p> <p><b>Nebojsa Lalic</b> - Pumps in T2D</p> <p><b>Jane Reusch</b> - Add on to basal insulin: patient centered considerations</p> <p><b>Oliver Schnell</b> - The role of AbA1c point of care testing in the management of diabetes and cardiovascular disease</p>	<p><b>Norbert Hermanns</b> - Medical Need for training courses for patients to make optimal usage of CGM (rtCGM and iscCGM)</p> <p><b>Hans DeVries</b> - CGM for hypoglycemia-prone patients</p> <p><b>Gérard Reach</b> - Decisions in the psychology of glucose monitoring</p>	<p><b>Philip Bourne</b> - The Five Pillars of Health Data Science – An Introduction</p> <p><b>Howard Zisser</b> - The Connected Patient</p> <p><b>Eyal Dassau</b> - Adaptive Automated Control of Diabetes – the Ultimate Personalized Diabetes Treatment</p> <p><b>Boris Kovatchev</b> - Building a virtual image of patient – the VIP approach to precision medicine for diabetes</p>		
<p><b>10:00-10:30</b></p>	<p><b>COFFEE BREAK</b></p>				

10:30- 11:30	PARALLEL SESSION ULTRA RAPID ACTING INSULINS AND TECHNOLOGY	ISPAD PARALLEL SESSION DIABETES TECHNOLOGY IN PEDIATRICS: ISPAD GUIDELINES UPDATE AND THE FUTURE	PARALLEL SESSION DO IT YOURSELF IN DIABETES	ORAL 6
	<p><b>David Klonoff</b> – Rapid Acting Insulin in CSII</p> <p><b>Bruce Bode</b> - Ultra Rapid acting insulin in Closed-Loop systems</p> <p><b>Klemen Dovc</b> – Rapid Acting Insulin, exercise and Closed-Loop</p>	<p><b>Jennifer Sherr</b> - Insulin pumps</p> <p><b>Martin de Bock</b> - Continuous glucose monitoring</p> <p><b>Martin Tauschmann</b> - Sensor augmented pump, hybrid closed loop, closed-loop</p>	<p><b>Aaron Kowalski</b> – Interoperable and Do-It-Yourself systems</p> <p><b>Lenka Petruzelkova</b> - The European perspective of DIY for Closed-Loop</p> <p><b>Dana Lewis</b> – "#WeAreNotWaiting: DIY Diabetes Data &amp; Research</p>	
11:30-12:30	<b>PLENARY SESSION BETA CELL REPLACEMENT STRATEGIES 2019</b>			
	<p><b>Pratik Chaudhary</b> - Future of Islet transplantation, latest outcomes and who should be referred</p> <p><b>Lorenzo Piemonti</b> – Future Landscape: Defining a successful outcome using stem cells as a source of insulin producing cells</p> <p><b>Jay Skyler</b> - Beta cell replacement 2019 and beyond</p>			
12:00-12:35	<b>CLOSING REMARKS AND FAREWELL – Moshe Phillip</b>			
12:35-13:20	<b>FAREWELL REFRESHMENTS (Exhibition Area)</b>			